CR20160502A - Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso - Google Patents
Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de usoInfo
- Publication number
- CR20160502A CR20160502A CR20160502A CR20160502A CR20160502A CR 20160502 A CR20160502 A CR 20160502A CR 20160502 A CR20160502 A CR 20160502A CR 20160502 A CR20160502 A CR 20160502A CR 20160502 A CR20160502 A CR 20160502A
- Authority
- CR
- Costa Rica
- Prior art keywords
- virus
- antibodies against
- methods
- influenza
- hemaglutinine
- Prior art date
Links
- 241000713196 Influenza B virus Species 0.000 title abstract 3
- 101710154606 Hemagglutinin Proteins 0.000 abstract 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 2
- 101710176177 Protein A56 Proteins 0.000 abstract 2
- 239000000185 hemagglutinin Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención proporciona anticuerpos de hemaglutinina contra el virus de la influenza B, composiciones que comprenden anticuerpos de hemaglutinina contra el virus de la influenza B y sus métodos de uso.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461971123P | 2014-03-27 | 2014-03-27 | |
| PCT/US2015/022758 WO2015148806A1 (en) | 2014-03-27 | 2015-03-26 | Anti-influenza b virus hemagglutinin antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20160502A true CR20160502A (es) | 2017-02-03 |
Family
ID=52829396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20160502A CR20160502A (es) | 2014-03-27 | 2015-03-26 | Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9745365B2 (es) |
| EP (1) | EP3122771A1 (es) |
| JP (1) | JP2017512471A (es) |
| KR (1) | KR20160135830A (es) |
| CN (1) | CN106132987A (es) |
| AR (1) | AR099855A1 (es) |
| AU (1) | AU2015235983A1 (es) |
| BR (1) | BR112016022113A2 (es) |
| CA (1) | CA2942820A1 (es) |
| CL (2) | CL2016002413A1 (es) |
| CR (1) | CR20160502A (es) |
| EA (1) | EA201691945A1 (es) |
| IL (1) | IL247870A0 (es) |
| MA (1) | MA39803A (es) |
| MX (1) | MX2016012530A (es) |
| PE (1) | PE20161376A1 (es) |
| PH (1) | PH12016501873A1 (es) |
| SG (1) | SG11201607945UA (es) |
| TW (1) | TW201620932A (es) |
| WO (1) | WO2015148806A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109154014A (zh) | 2016-05-10 | 2019-01-04 | 豪夫迈·罗氏有限公司 | 重组产生多肽期间减少三硫键的方法 |
| AU2018392728A1 (en) | 2017-12-22 | 2020-07-09 | Genentech, Inc. | Targeted integration of nucleic acids |
| CA3088194A1 (en) | 2018-01-26 | 2019-08-01 | Regeneron Pharmaceuticals, Inc. | Human antibodies to influenza hemagglutinin |
| JP2021519073A (ja) | 2018-03-29 | 2021-08-10 | ジェネンテック， インコーポレイテッド | 哺乳動物細胞におけるラクトジェニック活性の制御 |
| KR20210107057A (ko) | 2018-12-21 | 2021-08-31 | 제넨테크, 인크. | 핵산의 표적화 통합 |
| RU2714246C1 (ru) * | 2018-12-28 | 2020-02-13 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации | Моноклональные антитела, специфичные к различным штаммам вируса гриппа в |
| BR112022007923A2 (pt) * | 2019-10-28 | 2022-07-26 | Regeneron Pharma | Anticorpo recombinante isolado ou fragmento de ligação ao antígeno deste, composição farmacêutica, molécula de polinucleotídeo, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma da infecção por influenza |
| CN115348874A (zh) * | 2020-01-24 | 2022-11-15 | 里珍纳龙药品有限公司 | 蛋白质-抗病毒化合物偶联物 |
| TW202202620A (zh) | 2020-03-26 | 2022-01-16 | 美商建南德克公司 | 經修飾之哺乳動物細胞 |
| MX2022016453A (es) | 2020-06-24 | 2023-02-01 | Genentech Inc | Lineas celulares resistentes a la apoptosis. |
| CN116096907A (zh) | 2020-06-24 | 2023-05-09 | 基因泰克公司 | 核酸的靶向整合 |
| EP4204558A2 (en) | 2020-08-28 | 2023-07-05 | Genentech, Inc. | Crispr/cas9 multiplex knockout of host cell proteins |
| CN114316032B (zh) * | 2020-09-27 | 2022-12-27 | 东莞市朋志生物科技有限公司 | 抗乙型流感病毒的抗体、检测乙型流感病毒的试剂和试剂盒 |
| CA3215965A1 (en) | 2021-04-19 | 2022-10-27 | Amy Shen | Modified mammalian cells |
| JP2024521107A (ja) | 2021-05-21 | 2024-05-28 | ジェネンテック， インコーポレイテッド | 目的の組換え産物を産生するための修飾細胞 |
| WO2024104947A2 (en) | 2022-11-14 | 2024-05-23 | Janssen Vaccines & Prevention B.V. | Influenza b virus vaccines and uses thereof |
| WO2024107879A1 (en) | 2022-11-15 | 2024-05-23 | Genentech, Inc. | Combined transposon-mediated integration and targeted integration of nucleic acids into host cells |
| US20240240175A1 (en) | 2023-01-12 | 2024-07-18 | Genentech, Inc. | Combinatorial vector cloning and transfection strategies for targeted integration of nucleic acids |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2921928B1 (fr) | 2007-10-08 | 2011-03-04 | Sanofi Pasteur | Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal |
| BE1018561A3 (fr) | 2008-12-24 | 2011-03-01 | Galactic Sa | Procede de purification de l'acide lactique par cristallisation. |
| JP5780762B2 (ja) | 2008-12-25 | 2015-09-16 | 国立大学法人大阪大学 | 抗ヒトインフルエンザウイルス・ヒト型抗体 |
| BR112014000263B1 (pt) * | 2011-07-14 | 2022-01-18 | Janssen Vaccines & Prevention B.V. | Anticorpo isolado capaz de se ligar especificamente à proteína hemaglutinina (ha) dos subtipos de vírus influenza b, e, composição farmacêutica que o compreende |
| US9181328B2 (en) * | 2012-01-31 | 2015-11-10 | Osaka University | Human monoclonal antibodies broadly protective against influenza B virus and methods of using the same |
| NZ628382A (en) * | 2012-03-08 | 2017-03-31 | Janssen Vaccines & Prevention Bv | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof |
-
2015
- 2015-03-26 US US14/669,317 patent/US9745365B2/en not_active Expired - Fee Related
- 2015-03-26 EA EA201691945A patent/EA201691945A1/ru unknown
- 2015-03-26 CR CR20160502A patent/CR20160502A/es unknown
- 2015-03-26 SG SG11201607945UA patent/SG11201607945UA/en unknown
- 2015-03-26 PE PE2016001760A patent/PE20161376A1/es unknown
- 2015-03-26 MX MX2016012530A patent/MX2016012530A/es unknown
- 2015-03-26 CN CN201580016217.4A patent/CN106132987A/zh active Pending
- 2015-03-26 CA CA2942820A patent/CA2942820A1/en not_active Abandoned
- 2015-03-26 MA MA039803A patent/MA39803A/fr unknown
- 2015-03-26 KR KR1020167029658A patent/KR20160135830A/ko unknown
- 2015-03-26 BR BR112016022113A patent/BR112016022113A2/pt not_active IP Right Cessation
- 2015-03-26 TW TW104109843A patent/TW201620932A/zh unknown
- 2015-03-26 AU AU2015235983A patent/AU2015235983A1/en not_active Abandoned
- 2015-03-26 AR ARP150100900A patent/AR099855A1/es unknown
- 2015-03-26 WO PCT/US2015/022758 patent/WO2015148806A1/en active Application Filing
- 2015-03-26 EP EP15716285.0A patent/EP3122771A1/en not_active Withdrawn
- 2015-03-26 JP JP2016559331A patent/JP2017512471A/ja active Pending
-
2016
- 2016-09-18 IL IL247870A patent/IL247870A0/en unknown
- 2016-09-22 PH PH12016501873A patent/PH12016501873A1/en unknown
- 2016-09-26 CL CL2016002413A patent/CL2016002413A1/es unknown
-
2017
- 2017-07-24 US US15/657,433 patent/US20170320937A1/en not_active Abandoned
-
2018
- 2018-10-09 CL CL2018002874A patent/CL2018002874A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN106132987A (zh) | 2016-11-16 |
| EP3122771A1 (en) | 2017-02-01 |
| IL247870A0 (en) | 2016-11-30 |
| CA2942820A1 (en) | 2015-10-01 |
| US20150274812A1 (en) | 2015-10-01 |
| WO2015148806A1 (en) | 2015-10-01 |
| US9745365B2 (en) | 2017-08-29 |
| BR112016022113A2 (pt) | 2017-10-31 |
| US20170320937A1 (en) | 2017-11-09 |
| AU2015235983A1 (en) | 2016-10-06 |
| CL2018002874A1 (es) | 2018-12-14 |
| PH12016501873A1 (en) | 2017-01-09 |
| EA201691945A1 (ru) | 2017-02-28 |
| PE20161376A1 (es) | 2016-12-26 |
| JP2017512471A (ja) | 2017-05-25 |
| SG11201607945UA (en) | 2016-10-28 |
| TW201620932A (zh) | 2016-06-16 |
| AR099855A1 (es) | 2016-08-24 |
| KR20160135830A (ko) | 2016-11-28 |
| MA39803A (fr) | 2017-02-01 |
| MX2016012530A (es) | 2017-01-05 |
| CL2016002413A1 (es) | 2017-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018002874A1 (es) | Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016). | |
| CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
| PH12017500877B1 (en) | ANTI-CD79b ANTIBODIES AND METHODS OF USE | |
| CL2017000590A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| CR20180013A (es) | Anticuerpos anti-tau y métodos de uso. | |
| CR20170240A (es) | Anticuerpos anti-interleucina-33 y sus usos | |
| BR112016022658A2 (pt) | anticorpos anti-ox40 e métodos de uso | |
| CL2016002455A1 (es) | Anticuerpos multiespecíficos. | |
| BR112017008666A2 (pt) | anticorpos anti-fgfr2/3 e métodos de uso dos mesmos | |
| CR20160362A (es) | Anticuerpos anti-jagged1 y metodos de uso | |
| CR20150247A (es) | Anticuerpos de antihemaglutinina y métodos de uso | |
| EA201692467A1 (ru) | Вакцины против вируса гриппа и их применения | |
| CR20190271A (es) | Anticuerpos antitau y métodos de uso | |
| BR112016030968A2 (pt) | análogos de pridopidina, preparação e uso destes | |
| BR112016015706A2 (pt) | composto, uso do mesmo e composição farmacêutica | |
| BR112016006319A2 (pt) | inibidores de irak e usos dos mesmos | |
| CY1124521T1 (el) | Σκευασματα αντισωματος anti-cd19 | |
| MX2015016755A (es) | Reagrupamiento del virus de influenza. | |
| EA201692541A1 (ru) | Вакцины против вируса гриппа и их применения | |
| BR112017000456A2 (pt) | composições antivirais tópicas e métodos de uso das mesmas | |
| CR20170005A (es) | Derivados de insoindolina | |
| CL2019000049A1 (es) | Procesos para la preparación de oxipicolinamidas 4 - alkoxi - (acil o aquil). | |
| UY36221A (es) | Derivados de isoindolinona | |
| EA201790517A1 (ru) | Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции | |
| BR112017002090A2 (pt) | formulação de fator viii |